LB PHARMACEUTICALS INC (LBRX) earnings date
Mar 25, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 35% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-20
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 42 days, typically, give or take 21 (last 5 releases) |
Last 5 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | after close | 36 | 8-K |
| Q2 FY2026 | Tue, Aug 11, 2026 | before open | 42 | 8-K |
| Q1 FY2026 | Tue, May 12, 2026 | after close | 42 | 8-K |
| Q4 FY2025 | Thu, Mar 26, 2026 | after close | 85 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | before open | 37 | 8-K |
What they guided beta
| Q3 FY2026 | "Kozauer, M.D., as Chief Medical Officer and Joseph Miller as Chief Financial Officer On track for topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in 1H 2027 Presented new preclinical data supporting LB-102’s bimodal mechanism of action at the 39 th ECNP Congress Completed a private placement of $150 million to fund expansion of LB-102 into new indications Cash, cash equivalents, and short-term investments of $403.8 million as of September 30, 2026, expected to fund operations beyond Q2 2029, through multiple clinical milestones NEW YORK, November 5, 2" exhibit |
| Q3 FY2026 | "We remain on track to report topline results from our Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027." exhibit |
| Q3 FY2026 | "With a strong balance sheet and cash runway expected to extend beyond the second quarter of 2029, we believe we are exceptionally well positioned to maximize the broader potential of LB-102.”" exhibit |
| Q3 FY2026 | "Enrollment in the pivotal Phase 3 NOVA-2 trial evaluating the efficacy and safety of LB-102 in patients with acute schizophrenia continues to progress strongly with topline data expected in the first half of 2027." exhibit |
| Q3 FY2026 | "The Company expects to schedule a pre-New Drug Application meeting with the U.S. Food and Drug Administration (“FDA”) thereafter in the second half of 2027." exhibit |
| Q2 FY2026 | "LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027 Announced plans for pipeline expansion of LB-102 into new neuropsychiatric indications with strong mechanistic rationale and validating clinical and real-world experience from amisulpride Cash, cash equivalents, and marketable securities of $327.8 million as of June 30, 2026, and proceeds from recent $150.0 million private placement to fund pipeline expans" exhibit |
| Q2 FY2026 | "We are looking forward to our first pivotal trial readout and recently announced that, based on enrollment in our pivotal NOVA-2 trial in schizophrenia being more rapid than expected, we now project topline data readout in the first half of 2027, ahead of our prior guidance, and plan to schedule a pre-NDA meeting with the FDA soon thereafter in the second half of 2027." exhibit |
| Q2 FY2026 | "We are well positioned to advance multiple clinical programs and continue to expect topline data from our Phase 2 trial of LB-102 in bipolar depression in the first quarter of 2028 as well as data from our Phase 2 trial of LB-102 in adjunctive MDD in the first half of 2029.”" exhibit |
| Q2 FY2026 | "Based on enrollment projections in the pivotal Phase 3 NOVA-2 trial evaluating the efficacy and safety of LB-102 in patients with acute schizophrenia, topline data is expected in the first half of 2027." exhibit |
| Q2 FY2026 | "The Company expects to schedule a pre-NDA meeting with the FDA thereafter in the second half of 2027." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/LBRX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/LBRX
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/LBRX/"><img src="https://veritasdata.dev/embed/LBRX.svg" alt="LBRX earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/LBRX/)
Script
<script async src="https://veritasdata.dev/embed/LBRX.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/LBRX"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.